Biogen Idec beats Street

BIIB reported second quarter 2005 adjusted non-GAAP EPS of $0.43, beating the Street estimate by $0.07 and up 26% from $0.34 in the second quarter of 2004. The adjusted figure excludes merger-related charges and the sale of a manufacturing facility to Genentech (DNA) but includes charges of $0.04 per share related to Tysabri inventories that were written off during the quarter. ...